EIB President Werner Hoyer said: “To achieve the greatest global benefits we need solidarity, collaboration and partnerships, and we need it now. The EIB Group can bring financing and advisory support, creating firepower to develop a portfolio of COVID-19 vaccines. We also want to ensure that once we have vaccines, their supply is available everywhere. We have never before seen such a rapid and concerted effort across the globe to develop vaccines and treatments against a common enemy. Together with international partners at this global Pledging Conference we can speed up this work even further and ensure we use every instrument in our arsenal in the best way possible”.
EUR 770 million will be pledged in partnership and joint investment by the EIB Group and the European Commission for companies working on treatments, testing and vaccines. As part of this, the EIB will make an initial pledge today of 141 million from its own resources. The Commission will also announce the next milestones of a global campaign, which is to kick-off an ongoing rolling replenishment over the coming weeks.
Pledging and international cooperation
The European Union is teaming up with a broad range of international partners to bring this initiative to life. This includes co-hosting the pledging moment, securing funding pledges and firm political commitment to equitable access by all partner countries, businesses and organisations. To this end the European Commission have been in contact with partner countries, international organisations e.g. UN, WHO, G7, G20 and a series of expert worldwide lead organisations (e.g. Wellcome Trust, Bill and Melinda Gates Foundation, GAVI, Global Fund) as well as the pharmaceutical industry and scientific community.
EIB new initiatives in the health sector
Last week, the EIB announced a new Memorandum of Understanding with the WHO, an Advisory agreement with CEPI, a collaboration with the Israel Innovation Authority and a €50 million financing agreement with Pluristem to develop therapies for COVID-19 and increased cooperation with UN-Habitat.
Strengthening EIB support for health, life science and COVID-19 investment
In recent years the European Investment Bank has provided more than 2 billion EUR annually for health care and life science investment.
In the context of the COVID-19 pandemic, the EIB is currently assessing over 20 projects in the field of vaccine development, diagnostic and treatment, leading to potential investments in the 770 million EUR range.
The EIB is one of the largest public supporters of innovation in the EU. By supporting cutting-edge innovation and climate action, the EIB helps to make Europe more competitive. Since 2000, the Bank has invested more than EUR 210 billion in innovative projects, R&D, and skills and training. In 2019, the EIB helped to improve healthcare services for 12 million people. In addition, the Bank’s loans backed safer drinking water for 10 million people.